Augsti Intensificētās Fokusētās Elektromagnētiskās tehnoloģijas izmantošana sievietes seksuālās disfunkcijas ārstēšanā un seksualās funkcijas uzlabošanā: pirmā pieredze Latvijā
No Thumbnail Available
Date
2020
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Rīgas Stradiņa universitāte
Rīga Stradiņš University
Rīga Stradiņš University
Abstract
Ievads
Seksuālā veselība ir ne tikai cieši saistīta ar sievietes reproduktīvo veselību, bet ir arī daļa no kopējās veselības definīcijas. Tieši tāpēc sieviešu seksuālās disfunkcijas (SSD) profilaksei, diagnostikai un ārstēšanai ir nenoliedzama loma sieviešu labklājības jēdzienā. Šajā pētījumā tika analizētas HIFEM tehnoloģijas perspektīvas SSD ārstēšanā un sieviešu seksuālās veselības uzlabošanā.
Materiāli un metodes
40 sievietēm vecumā no 25 līdz 45 gadiem, kuras tika atlasītas pēc noteiktiem kritērijiem, tika veiktas desmit HIFEM tehnoloģijas procedūras.
Dati tika iegūti no anketām, kas bija aizpildītas pirms pirmās, pēc 5. un 10. procedūras, izmantojot internacionāli validēto sieviešu seksuālās funkcijas indeksu (SSFI) - pēc kura par SSD diagnozi liecina SSFI <26,55 - un atbildes uz papildus jautājumiem.
Dati tika apstrādāti ar Microsoft Excel un IBM SPSS Statistics 22.0.
Rezultāti
No pētījumu grupas 87,5% (n = 35) izgāja pilnu procedūru ciklu. 69% (n = 24) no viņiem bija SSD. 60% (n = 21) pacienšu bija pirmdzemdētajas. 50% (n = 7) no tiem, kuriem bija ≥ 1 bērns, dzemdību laikā bija pielietota episiotomija vai bija plīsumi. Vidējais SSFI pirms ārstēšanas sākuma bija 22,50 (4,85) ar vismazāko rādītāju Vēlmes 3,10 (1,00) domēnā. Pēc 5. procedūras vidējais SSFI bija 27,17 (3,58), pēc 10. procedūras - 26,92 (3,97) ar visizteteiktākajām izmaiņām Orgasma domēnā: 0,84 (1,37) pēc 5. un 0,93 (1,6) pēc 10. procedūras. SSFI vidējās izmaiņas bija statistiski nozīmīgas (p <0,05) pēc 5. un 10. procedūras SSD grupai: 5,15 (3,37) un 7,12 (4,81) respektīvi, un grupā bez SSD: 1,89 (2,08) un -0,13 (1,9) pēc 5. un 10. vietas, respektīvi. 8,5% (n = 3) attīstījās blakusparādības pēc 4., 7. un 10. procedūras.
Secinājumi
HIFEM tehnoloģiju var izmantot SSD ārstēšanā vai seksuālās funkcijas uzlabošanā, bet profilaktiskas lietošanas gadījumā katra situācija jāapsver individuāli, ņemot vērā sākotnējo muskuļu tonusu, iespējamo labumu trūkumu vai pat blakusparādību rašanos.
Objectives Sexual health is not only closely linked to woman's reproductive health but is also a part of the overall health definition. That is why prevention, diagnosis and treatment of female sexual dysfunction (FSD) play an undeniable role in the concept of female wellbeing. By this study were analyzed perspectives of HIFEM technology in treatment of FSD and improvement of women sexual health. Materials and Methods 40 women, aged 25 to 45, selected according to specific criteria, underwent ten HIFEM technology procedures. Data was obtained from questionnaires, filled before the 1st, after the 5th and the 10th procedures, using validated Female Sexual Function Index (FSFI) – suggesting FSFI<26.55 for the diagnosis of FSD – and supplementary questions. Data was processed with Microsoft Excel and IBM SPSS Statistics 22.0. Results From the selected research group, 87.5% (n=35) have underwent full procedure cycle. 69%(n=24) of them had FSD. 60%(n=21) of patients were nullipara. 50%(n=7) of those, who had ≥ 1child had episiotomy or ruptures during labor. Mean(SD) FSFI before the start of treatment was 22.50(4.85) with the lowest numbers in Desire 3.10(1.00) domain. After the 5th procedure mean FSFI was 27.17(3.58). after the 10th procedure – 26.92(3.97) with the biggest changes in Orgasm domain 0.84(1.37) after the 5th; 0.93(1.6) after the 10th. FSFI mean changes were statistically significant (p<0.05) after the 5th and 10th procedure for FSD group: 5.15(3.37) and 7.12(4.81) respectively; and non-FSD group: 1.89(2.08) and -0.13(1.9) after the 5th and 10th respectively. 8.5% (n=3) developed side effects after 4th, 7th and 10th procedure. Conclusions HIFEM technology could be used for treatment of FSD or improvement of sexual function, however in case of prophylactic use, each situation should be considered individually with the regard to initial muscle tonus, possible lack of benefit or even emersion of side effects.
Objectives Sexual health is not only closely linked to woman's reproductive health but is also a part of the overall health definition. That is why prevention, diagnosis and treatment of female sexual dysfunction (FSD) play an undeniable role in the concept of female wellbeing. By this study were analyzed perspectives of HIFEM technology in treatment of FSD and improvement of women sexual health. Materials and Methods 40 women, aged 25 to 45, selected according to specific criteria, underwent ten HIFEM technology procedures. Data was obtained from questionnaires, filled before the 1st, after the 5th and the 10th procedures, using validated Female Sexual Function Index (FSFI) – suggesting FSFI<26.55 for the diagnosis of FSD – and supplementary questions. Data was processed with Microsoft Excel and IBM SPSS Statistics 22.0. Results From the selected research group, 87.5% (n=35) have underwent full procedure cycle. 69%(n=24) of them had FSD. 60%(n=21) of patients were nullipara. 50%(n=7) of those, who had ≥ 1child had episiotomy or ruptures during labor. Mean(SD) FSFI before the start of treatment was 22.50(4.85) with the lowest numbers in Desire 3.10(1.00) domain. After the 5th procedure mean FSFI was 27.17(3.58). after the 10th procedure – 26.92(3.97) with the biggest changes in Orgasm domain 0.84(1.37) after the 5th; 0.93(1.6) after the 10th. FSFI mean changes were statistically significant (p<0.05) after the 5th and 10th procedure for FSD group: 5.15(3.37) and 7.12(4.81) respectively; and non-FSD group: 1.89(2.08) and -0.13(1.9) after the 5th and 10th respectively. 8.5% (n=3) developed side effects after 4th, 7th and 10th procedure. Conclusions HIFEM technology could be used for treatment of FSD or improvement of sexual function, however in case of prophylactic use, each situation should be considered individually with the regard to initial muscle tonus, possible lack of benefit or even emersion of side effects.
Description
Medicīna
Medicine
Veselības aprūpe
Health Care
Medicine
Veselības aprūpe
Health Care
Keywords
Sievietes seksuālā disfunkcija, seksuālā veselība, Female sexual dysfunction, sexual health